Figure 2.

Reduction in MDSC and dynamics of ERK phosphorylation on c-Kit⁺ MDSCs during tivozanib therapy. (A) Representative histogram offset showing frequency of CD11b⁺CD33⁺ MDSCs measured at pre, 28–35d and 160d of tivozanib treatment. (B) Frequency and (C) absolute numbers of MDSCs pre vs 28–35. (D) Representative histogram offset showing frequency of c-Kit⁺ MDSCs measured at pre, 28–35d and 160d of tivozanib treatment. (E) Frequency and (F) absolute numbers of c-Kit⁺ MDSCs pre vs 28–35. (G) Representative histogram offset showing frequency of c-Kit⁺pERK⁺ MDSCs measured at pre, 28–35d and 160d of tivozanib treatment. (H) Frequency and (I) absolute numbers of c-Kit⁺pERK⁺ MDSCs pre vs 28–35. Each symbol represents an individual HCC patient. Frequencies of MDSCs were calculated based on CD14⁻HLA-DR⁻ population **** P < 0.0001, *** P < 0. 001, ** P < 0.01, * P < 0.05, paired t-test, n = 17.